ProCE Banner Activity

An Expert’s Guide to ASCO 2024: Preview of the Top Abstracts

Conference Coverage
Clinical Thought

Experts highlight their choice of key studies being presented at the 2024 ASCO Annual Meeting. CCO’s Independent Conference Coverage will include timely summaries, expert analysis, and practical implications of the latest research and developments in oncology to help you stay at the forefront of advances in cancer care.

Released: May 30, 2024

Expiration: May 29, 2025

Share

Faculty

Allison Betof Warner

Allison Betof Warner, MD, PhD

Assistant Professor of Medicine (Oncology)
Director, Melanoma Medical Oncology Program
Director, Solid Tumor Cellular Therapy 
Leader, Melanoma & Cutaneous Oncology Clinical Research Group
Stanford University School of Medicine
Stanford, California

Sara A. Hurvitz

Sara A. Hurvitz, MD, FACP

Professor of Medicine
Head, Division of Hematology and Oncology
Department of Medicine, UW Medicine
Senior Vice President
Clinical Research Division
Fred Hutchinson Cancer Center
Seattle, Washington

Kevin Kalinsky

Kevin Kalinsky, MD, MS

Division Director, Medical Oncology
Professor, Department of Hematology and Medical Oncology
Winship Cancer Institute at Emory University
Atlanta, Georgia

Shaji K. Kumar

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Chair, Myeloma, Amyloidosis and Dysproteinemia Group
Research Chair, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Natasha Leighl

Natasha Leighl, MD, MMSc, FRCPC, FASCO

Lung Medical Oncology Site Lead
OSI Pharmaceuticals Foundation Chair
Princess Margaret Cancer Centre
Professor of Medicine
University of Toronto
Toronto, Canada

Zofia Piotrowska

Zofia Piotrowska, MD

Assistant Professor of Medicine
Massachusetts General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

Jeffrey P. Sharman

Jeffrey P. Sharman, MD

Medical Director of Hematology Research
Sarah Cannon at Willamette Valley Cancer Institute
Eugene, Oregon

Eunice S. Wang

Eunice S. Wang, MD

Chief, Leukemia and Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Inc., GSK, Lilly, Merck Sharp & Dohme, LLC, Novartis Pharmaceuticals Corporation, and Sanofi.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

GSK

Lilly

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Sanofi

Disclosure

Primary Author

Allison Betof Warner, MD, PhD

Assistant Professor of Medicine (Oncology)
Director, Melanoma Medical Oncology Program
Director, Solid Tumor Cellular Therapy 
Leader, Melanoma & Cutaneous Oncology Clinical Research Group
Stanford University School of Medicine
Stanford, California

Allison Betof Warner, MD, PhD: consultant: BluePath Solutions, Bristol Myers Squibb, Immatics, Instil Bio, Iovance Biotherapeutics, Lyell Immunopharma, Merck, Novartis, Pfizer; researcher (paid to institution): Bristol Myers Squibb, Iovance Biotherapeutics, Obsidian Therapeutics.

Sara A. Hurvitz, MD, FACP

Professor of Medicine
Head, Division of Hematology and Oncology
Department of Medicine, UW Medicine
Senior Vice President
Clinical Research Division
Fred Hutchinson Cancer Center
Seattle, Washington

Sara A. Hurvitz, MD, FACP: researcher: Ambrx, Amgen, Arvinas, AstraZeneca, Bayer, Celcuity, CytomX, Daiichi Sankyo, Dantari, Dignitana, Genentech/Roche, G1 Therapeutics, Gilead, Greenwich, Life Sciences, GlaxoSmithKline, Immunomedics, Lilly, Loxo, MacroGenics, Novartis, OBI Pharma, Orinove, Orum, Pfizer, Phoenix Molecular Designs, Puma, Radius, Samumed, Sanofi, Seattle Genetics/Seagen, Zymeworks; individual publicly traded stock/stock options: ROM Tech.

Kevin Kalinsky, MD, MS

Division Director, Medical Oncology
Professor, Department of Hematology and Medical Oncology
Winship Cancer Institute at Emory University
Atlanta, Georgia

Kevin Kalinsky, MD, MS: consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo, Genentech/Roche, Immunomedics, Menarini, Mersana, Merck, Myovant, Puma Technology, Seattle Genetics, Silicon Biosystems, Takeda.

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Chair, Myeloma, Amyloidosis and Dysproteinemia Group
Research Chair, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Shaji K. Kumar, MD: consultant/advisor/speaker: AbbVie, Amgen, ArcellX, BD Biosciences; BeiGene, Bristol Myers Squibb, Carsgen, GlaxoSmithKline, Janssen, K36, Moderna, Pfizer, Regeneron, Roche/Genentech, Sanofi, Takeda; research (paid to institution): AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Carsgen, GlaxoSmithKline, Gracell Bio, Janssen, Oricell, Roche/Genentech, Sanofi, Takeda, Telogenomics.

Natasha Leighl, MD, MMSc, FRCPC, FASCO

Lung Medical Oncology Site Lead
OSI Pharmaceuticals Foundation Chair
Princess Margaret Cancer Centre
Professor of Medicine
University of Toronto
Toronto, Canada

Natasha Leighl, MD, MMSc, FRCPC, FASCO: researcher (paid to institution): AstraZeneca, Bristol Myers Squibb, Inivata/NeoGenomics, Lilly, Merck Sharp & Dohme, Pfizer; consultant/advisor/speaker: AstraZeneca, Guardant Health, Janssen, Merck Sharp & Dohme, Roche, Sanofi.

Zofia Piotrowska, MD

Assistant Professor of Medicine
Massachusetts General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

Zofia Piotrowska, MD: consultant/advisor/speaker: AstraZeneca, Bayer, Black Diamond Therapeutics, Blueprint Medicines, Boehringer Ingelheim, Daiichi Sankyo, Janssen, Lilly, Merck, Sanofi, Taiho, Takeda; researcher: AbbVie, AstraZeneca, Blueprint Medicines, Cullinan Oncology, Daiichi Sankyo, Janssen, Novartis, Spectrum, Takeda, Tesaro/GlaxoSmithKline; data safety monitoring committee: Genentech.

Jeffrey P. Sharman, MD

Medical Director of Hematology Research
Sarah Cannon at Willamette Valley Cancer Institute
Eugene, Oregon

Jeffrey P. Sharman, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, BeiGene, Janssen, Lilly.

Eunice S. Wang, MD

Chief, Leukemia and Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Eunice S. Wang, MD: consultant/advisor/speaker: AbbVie, Blueprint, Bristol Myers Squibb, CTI Biopharma, Daiichi Sankyo, Gilead, GlaxoSmithKline, Immunogen, Johnson & Johnson, Kite, Kura, Novartis, Qiagen, Rigel, Schrodinger, Sellas, Stemline, Sumitomo, Syndax.